Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and …
Summary COVID-19-associated pulmonary mucormycosis (CAPM) remains an
underdiagnosed entity. Using a modified Delphi method, we have formulated a consensus …
underdiagnosed entity. Using a modified Delphi method, we have formulated a consensus …
Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric …
Invasive opportunistic fungal diseases (IFDs) are important causes of morbidity and mortality
in paediatric patients with cancer and those who have had an allogeneic haemopoietic stem …
in paediatric patients with cancer and those who have had an allogeneic haemopoietic stem …
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial
JA Maertens, G Rahav, DG Lee, A Ponce-de-León… - The Lancet, 2021 - thelancet.com
Background Voriconazole has been recommended as primary treatment for patients with
invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have …
invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have …
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3 …
JA Maertens, II Raad, KA Marr, TF Patterson… - The Lancet, 2016 - thelancet.com
Background Isavuconazole is a novel triazole with broad-spectrum antifungal activity. The
SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients …
SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients …
[HTML][HTML] Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline
AJ Ullmann, JM Aguado, S Arikan-Akdagli… - Clinical Microbiology …, 2018 - Elsevier
Abstract The European Society for Clinical Microbiology and Infectious Diseases, the
European Confederation of Medical Mycology and the European Respiratory Society Joint …
European Confederation of Medical Mycology and the European Respiratory Society Joint …
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Background Mucormycosis is an uncommon invasive fungal disease with high mortality and
few treatment options. Isavuconazole is a triazole active in vitro and in animal models …
few treatment options. Isavuconazole is a triazole active in vitro and in animal models …
ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013
OA Cornely, S Arikan‐Akdagli… - Clinical Microbiology …, 2014 - Wiley Online Library
Abstract These European Society for Clinical Microbiology and Infectious Diseases and
European Confederation of Medical Mycology Joint Clinical Guidelines focus on the …
European Confederation of Medical Mycology Joint Clinical Guidelines focus on the …
Isavuconazole: a new broad-spectrum triazole antifungal agent
MH Miceli, CA Kauffman - Clinical Infectious Diseases, 2015 - academic.oup.com
Isavuconazole is a new extended-spectrum triazole with activity against yeasts, molds, and
dimorphic fungi. It is approved for the treatment of invasive aspergillosis and mucormycosis …
dimorphic fungi. It is approved for the treatment of invasive aspergillosis and mucormycosis …
Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of …
Breakthrough invasive fungal infections (IFI s) have emerged as a significant problem in
patients receiving systemic antifungals; however, consensus criteria for defining …
patients receiving systemic antifungals; however, consensus criteria for defining …
[HTML][HTML] Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in …
Mucormycosis is an emerging cause of infectious morbidity and mortality in patients with
hematologic malignancies. However, there are no recommendations to guide diagnosis and …
hematologic malignancies. However, there are no recommendations to guide diagnosis and …